EPOR Gene Therapy Patent, Ensoma, Inc.
Summary
The European Patent Office published patent application EP4319773A1 for Ensoma, Inc., covering modifications to EPOR-encoding nucleic acids for gene therapy applications. The patent application names five inventors and is classified under multiple IPC codes including C12N (nucleic acids, genetic engineering), C07K (peptides/proteins), and A61K (preparations for medical use). The application designates all EPC contracting states.
What changed
The EPO published application EP4319773A1 titled 'Modification of EPOR-encoding nucleic acids' filed by Ensoma, Inc., covering genetic modifications related to the erythropoietin receptor (EPOR) for therapeutic applications. The technology falls under IPC classifications including C12N 15/113 (nucleic acid sequences), C07K 14/715 (cytokine proteins), C12N 9/10 (enzymes), and C12N 9/22 (nucleic acid enzymes), with A61K 38/00 covering therapeutic preparations. The designated states cover all EPC contracting states (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR).\n\nPharmaceutical and biotechnology companies engaged in gene therapy, erythropoietin-related research, or cytokine-based therapeutics should review this patent to assess freedom-to-operate considerations and potential licensing needs. Companies developing similar genetic modifications or therapeutic applications involving EPOR should evaluate potential overlap and consider patent monitoring strategies for the prosecution of this application through to grant.
What to do next
- Review patent claims for potential overlap with current gene therapy R&D programs
- Conduct freedom-to-operate analysis if developing EPOR-related therapeutics
- Monitor application prosecution for any narrowing of claims during examination
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
MODIFICATION OF EPOR-ENCODING NUCLEIC ACIDS
Publication EP4319773A1 Kind: A1 Mar 25, 2026
Applicants
Ensoma, Inc.
Inventors
BASHYAM, Ashvin Reddy, CLARK, Martha Ann, AU, Pak Wai, PARMAR, Kush M., BARCLAY FISHER, Adam
IPC Classifications
C12N 15/113 20100101AFI20260218BHEP C07K 14/715 20060101ALI20260218BHEP C12N 15/52 20060101ALI20260218BHEP C12N 9/10 20060101ALI20260218BHEP A61K 38/00 20060101ALN20260218BHEP C12N 9/22 20060101ALN20260218BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Get daily alerts for ChangeBridge: EPO Bulletin - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Peptides (C07K) publishes new changes.